The US-based protein purification technology developer shifted its manufacturing base to North Carolina two years ago and has now secured three licences from NC State.

GV is the largest shareholder in the cancer immunotherapy developer, which has filed for a $100m initial public offering.

Lonza Group has appointed venture firm Prolog Ventures to manage a fund that will invest in consumer health technology developers.

Monash University has spun out Cincera Therapeutics, which will work on treatments for metabolic syndrome and type-2 diabetes-related conditions.

The microbiome profiling business is the result of collaboration between two former Roche employees and researchers from UConn and Yale New Haven Hospital.

Roche has agreed to acquire oncology research platform Flatiron in a deal that valued it at $2.15bn, giving GV what would be its fifth latest life sciences exit since the start of November.

Nebula Genomics aims to launch a genomics platform that will let users securely monetise their personal data and gain medical insights.